Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin’s lymphoma: a reflection of disease infiltration or just inflammation?
- 684 Downloads
18F-FDG PET has been successfully evaluated in the management of Hodgkin’s lymphoma (HL) and the most recent international guidelines recommended 18F-FDG PET for initial staging and final therapeutic assessment. However, 18F-FDG PET diffuse bone marrow uptake (BMU) and splenic uptake (SU) are frequently observed at the initial imaging and remain difficult to analyse. The aim of this retrospective study was to evaluate the significance of 18F-FDG diffuse BMU and SU in initial staging of HL.
A total of 106 patients (median age: 31 years, range: 9–81, 51 female, 55 male) underwent 18F-FDG PET/CT for initial staging of HL. BMU level was assessed visually according to liver uptake (1 = below liver uptake, 2 = corresponding to liver uptake, 3 = above liver uptake) and semi-quantitatively using the maximum standardized uptake value (SUVmax) measured in the sacral area. SU was assessed visually according to liver uptake (1 = below liver uptake, 2 = corresponding to liver uptake, 3 = above liver uptake). These data were compared with the patient’s characteristics including sex, age, Ann Arbor staging, bulky disease (tumour burden > 10 cm), presence of B symptoms, bone foci on PET (n = 106), bone marrow involvement (BMI) on biopsy (n = 75), leukocyte count (n = 74), lactic dehydrogenase (LDH) (n = 87), C-reactive protein (CRP) (n = 83) and fibrinogen (n = 60). Univariate and multivariate analyses were performed.
Multivariate analysis found an independent correlation between BMU visual grading and CRP level (p = 0.007). For semi-quantitative BMU evaluation, multivariate analysis found an independent correlation between sacral SUVs and CRP level (p = 0.032) and Ann Arbor stage (p = 0.005). No BMI was found in patients who presented with SUVmax below 3.4. For splenic evaluation, multivariate analysis found an independent correlation between SU and splenic foci (p = 0.034). No statistical link was found between SU and inflammatory markers.
Our study demonstrates that diffuse BMU at initial staging of HL could be due to bone marrow involvement but more likely to bone marrow inflammatory change and that diffuse SU in contrast is probably more associated with disease involvement than with inflammatory change.
KeywordsFDG PET Hodgkin’s lymphoma Bone marrow involvement Inflammation
- 1.Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721–8. doi: 10.1007/s002590050275.CrossRefPubMedGoogle Scholar
- 4.Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571–8. doi: 10.1200/JCO.2006.08.2305.CrossRefPubMedGoogle Scholar
- 6.Juweid ME. Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2006;259–65:510–1.Google Scholar
- 23.Ribrag V, Vanel D, Leboulleux S, Lumbroso J, Couanet D, Bonniaud G, et al. Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy. Eur J Radiol 2008;66:325–31. doi: 10.1016/j.ejrad.2007.06.014.CrossRefPubMedGoogle Scholar
- 29.Rueffer U, Sieber M, Josting A, Breuer K, Grotenhermen F, Bredenfeld H, et al. Prognostic factors for subdiaphragmatic involvement in clinical stage I-II supradiaphragmatic Hodgkin’s disease: a retrospective analysis of the GHSG. Ann Oncol 1999;10:1343–8. doi: 10.1023/A:1008377629280.CrossRefPubMedGoogle Scholar
- 31.Tubiana M, Henry-Amar M, Hayat M, Burgers M, Qasim M, Somers R, et al. Prognostic significance of the number of involved areas in the early stages of Hodgkin’s disease. Cancer 1984;54:885–94. doi: 10.1002/1097-0142(19840901)54:5<885::AID-CNCR2820540522>3.0.CO;2-B.CrossRefPubMedGoogle Scholar
- 35.Munker R, Stengel A, Stäbler A, Hiller E, Brehm G. Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin’s disease. Verification by laparotomy in 100 cases. Cancer 1995;76:1460–6. doi: 10.1002/1097-0142(19951015)76:8<1460::AID-CNCR2820760825>3.0.CO;2-Y.CrossRefPubMedGoogle Scholar